Guardant Health
GH
#3260
Rank
NZ$6.12 B
Marketcap
$49.60
Share price
-3.64%
Change (1 day)
32.33%
Change (1 year)
Guardant Health is an American company developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors.

Guardant Health (GH) - Total debt

Total debt on the balance sheet as of September 2024 : NZ$2.28 Billion

According to Guardant Health 's latest financial reports the company's total debt is NZ$2.28 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Guardant Health - Total debt on balance sheet (from 2017 to 2024)

Total debt by year

Year Total debt Change
2023-12-31NZ$2.14 B-0.74%
2022-12-31NZ$2.15 B7.23%
2021-12-31NZ$2.01 B69.83%
2020-12-31NZ$1.18 B1874.38%
2019-12-31NZ$59.98 M
2018-12-31N/A-100%
2017-12-31NZ$0.92 M-96.23%
2016-12-31NZ$24.59 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
NZ$0.74 B-67.33%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$1.51 B-33.42%๐Ÿ‡บ๐Ÿ‡ธ USA